Cary Street Partners Investment Advisory’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-150	Closed	-$8.85K	–	1185
2023 Q3	$8.85K	Hold	150	–	–	﹤0.01%	1331
2023 Q2	$8.96K	Hold	150	–	–	﹤0.01%	1275
2023 Q1	$8.76K	Hold	150	–	–	﹤0.01%	1185
2022 Q4	$9.31K	Buy	+150	New	+$9.02K	﹤0.01%	1177
2020 Q4	–	Sell	-51	Closed	-$3K	–	593
2020 Q3	$3K	Buy	+51	New	+$2.75K	﹤0.01%	883

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RIG

RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cary Street Partners Investment Advisory's IHE Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2023, closing a stake of 150 shares — an estimated $8.85K sold.

Cary Street Partners Investment Advisory first reported a position in IHE in Q3 2020 and held it in 5 quarters. The position peaked at $9.31K in Q4 2022. 137 funds tracked by Wall St. Rank hold IHE as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 150 iShares US Pharmaceuticals ETF shares in Q4 2023, an estimated $8.85K.
Cary Street Partners Investment Advisory first reported a position in iShares US Pharmaceuticals ETF in Q3 2020 and held it in 5 quarters.
Cary Street Partners Investment Advisory's iShares US Pharmaceuticals ETF position peaked at $9.31K in Q4 2022.
137 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.